ERYTECH Pharma S.A.
Develops red blood cell-based therapies for cancer and orphan diseases.
ERYP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417360 (+2 more)
- LEI:
- 969500U8ZZCODU8A9374
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://phaxiam.com/
- Sector:
- Manufacturing
Description
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-11-25 07:30 |
ERYTECH annonce la publication des résultats de son étude de phase 2b avec erya…
|
French | 770.0 KB | ||
| 2019-11-14 23:00 |
ERYTECH présentera à l’occasion de la Jefferies 2019 Healthcare Conference à Lo…
|
French | 254.6 KB | ||
| 2019-11-14 23:00 |
ERYTECH to Present at Jefferies 2019 Healthcare Conference in London
|
English | 251.7 KB | ||
| 2019-11-07 23:00 |
ERYTECH fait le point sur ses activités et publie ses résultats du troisième tr…
|
French | 463.5 KB | ||
| 2019-11-07 23:00 |
ERYTECH Provides Business Update and Reports Financial Results for the Third Qu…
|
English | 460.4 KB | ||
| 2019-11-05 23:00 |
ERYTECH tiendra un webcast le 8 novembre 2019 à l’occasion de ses résultats du …
|
French | 399.5 KB | ||
| 2019-11-05 23:00 |
ERYTECH to Host Third Quarter 2019 Conference Call and Business Update on Nove…
|
English | 314.6 KB | ||
| 2019-11-05 18:00 |
Information mensuelle relative au nombre total de droits de vote et d’actions c…
|
French | 217.1 KB | ||
| 2019-11-05 18:00 |
Monthly information related to total number of voting rights and shares composi…
|
English | 196.9 KB | ||
| 2019-11-04 07:30 |
ERYTECH Achieves Milestones in TRYbeCA1 Phase 3 Trial of Eryaspase in Second-li…
|
English | 421.4 KB | ||
| 2019-11-04 07:30 |
ERYTECH franchit des étapes importantes dans l’étude de Phase 3 TRYbeCA1 avec e…
|
French | N/A | ||
| 2019-09-18 14:54 |
Half-Year Financial Report 30 June 2019
|
English | 1008.2 KB | ||
| 2019-09-18 14:54 |
Rapport financier semestriel 30 juin 2019
|
French | 1004.1 KB | ||
| 2019-09-17 23:00 |
ERYTECH fait le point sur ses activités et publie ses résultats semestriels 2019
|
French | 466.7 KB | ||
| 2019-09-17 23:00 |
ERYTECH Provides Business Update and Reports Financial Results for the First Ha…
|
English | 459.8 KB |
Automate Your Workflow. Get a real-time feed of all ERYTECH Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ERYTECH Pharma S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ERYTECH Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-23 | N/A | Other | Other | 3,697,533 | 2,255,495.13 EUR |
| 2023-06-23 | N/A | Other | Other | 71,839 | 43,821.79 EUR |
| 2023-06-23 | N/A | Other | Other | 54,862 | 33,465.82 EUR |
Peer Companies
